Post-operative survival and use of systemic therapy in metastatic long-bone disease: 12 years of institutional experience.

ABSTRACT:

Background

Survival prediction in metastatic long-bone disease is essential for surgical decision-making, yet the performance of legacy prognostic models has declined in the era of immunotherapy and molecularly targeted agents. As these systemic therapies become routine, treatment patterns themselves may influence survival in ways not captured by earlier models. We, therefore, quantified preoperative systemic therapy use over the last decade and evaluated its association with postoperative overall survival in patients undergoing surgery for long-bone metastases.

Methods

We conducted a retrospective cohort study of 975 consecutive adults who underwent surgery for long-bone metastases at two affiliated tertiary centers between January 2010 and June 2022. Preoperative systemic

SUBMITTER: de Groot TM 

PROVIDER: S-EPMC12925594 | biostudies-literature | 2026 Apr

REPOSITORIES: biostudies-literature